E7.3

Medication Trials & Response

Each trial needs an adequate duration, an adequate dose, and an explicit decision point. Inadequate trials inflate "treatment resistance."

Encounter card

Setting

When starting a new medication, deciding whether a trial has worked, deciding when to switch or augment.

Opening move

Define the trial parameters upfront — target dose, expected timeline, criteria for response. Reassess at the predetermined decision point with structured measures (PHQ-9, GAD-7) when available.

Sample language

"Here's the plan: we'll start sertraline at 50mg, and if it's tolerable, increase to 100mg after 2 weeks. We'll meet in 4 weeks and 8 weeks. At 8 weeks, if you're less than 50% improved, we'll discuss switching."
"You're at week 6 of fluoxetine 40mg. Let's look at the PHQ-9 trajectory and decide whether this is working."
"A response is at least 50% improvement; remission is symptom-free or close to it. We aim for remission, not just response."

Listen for

Patient's sense of change vs measured change. Side effects limiting adequate trial. Adherence questions. Patient discouragement that may need to be addressed.

Common pitfalls

Calling a trial "failed" before adequate dose and duration. Inadequate dose escalation due to side effect anxiety. Inadequate duration because of clinician impatience. Switching when augmentation might serve better. No structured measure to track response.

Red flags / escalate: Multiple "failed trials" in the chart that were actually inadequate. Patient discouragement leading to disengagement.

Documentation

Drug, dose, duration, response (PHQ-9 trajectory), AEs, decision (continue, increase, augment, switch).

An adequate trial is a defined trial. Don't accumulate failures that were never given a fair chance.

Warm grey-tinted clinical notebook page, muted teal accent. Adequate trial: target dose + adequate duration + structured measurement. Margin clusters on each.

A medication trial is not just "we tried it." A proper trial requires adequate dose, adequate duration, and an explicit decision point at which response is assessed. Many "treatment-resistant" patients have actually failed a series of inadequate trials, and the path forward isn't more aggressive treatment but better-conducted trials.

Adequate dose. Each medication has a therapeutic range. Below the therapeutic range, the trial is testing inadequate exposure, not the medication itself. Sertraline 50 mg for 4 weeks isn't a failed sertraline trial; it's an inadequate trial of sertraline at sub-therapeutic dose. Push to therapeutic dose before declaring non-response.

Adequate duration. Most antidepressants require 6-8 weeks at therapeutic dose for full effect; mood stabilizers may require longer; antipsychotics need 4-6 weeks for full antipsychotic effect. The trial that lasted 2 weeks at a starter dose hasn't been given a fair chance. Patients often want faster judgment; counsel the timeline at the start.

Explicit decision point. Set in advance what you'll be looking at: "At 4 weeks we'll check in; if PHQ-9 hasn't improved by 5 points, we'll consider increasing. At 8 weeks at maximum dose, if less than 50 percent improvement, we'll discuss switching." Without explicit decision points, trials drift indefinitely.

Use structured measures when available. PHQ-9 for depression, GAD-7 for anxiety, YBOCS for OCD, AIMS for tardive dyskinesia. The patient's subjective "I think I'm doing a little better" is informative; the measured improvement quantifies it. Structured measures reduce reliance on memory of how things were and produce trackable trajectories.

Response versus remission. Response is 50 percent improvement; remission is symptom-free or close. Aim for remission, not just response. The patient with response but persistent residual symptoms has a higher recurrence risk and lower functional level than the patient who achieves remission. Push for remission when possible.

Document trials specifically — drug, dose, duration, response, adverse effects. The chart should show what was tried adequately and what wasn't. This protects future clinical decisions and supports appropriate next steps.

Response (≥50% improvement) vs remission (symptom-free or near). Aim for remission. Margin notes on the difference.

The anchor

A medication trial requires adequate dose, adequate duration, and an explicit decision point. Use structured measures to track response. Don't accumulate inadequate trials.

At decision point — partial response (consider increasing or augmenting), no response (switch class), full response (continue with maintenance plan). Margin clusters on each path.

Prove it

A patient on sertraline 50mg for 4 weeks reports "it's not working." How do you decide what to do?

This connects to

E3.2

Past Psychiatric History

Where prior trial adequacy is evaluated.

E7.4

Adherence

A precondition of adequate trial.

Locked concepts unlock as you reach them on the path.